Ostenil® line

®
Ostenil line
®
Decrease Joint Pain
Improve Joint Function
A Swiss pharmaceutical company with more than 30 years experience
in hyaluronic acid-based products.
In-house ISO certified manufacturing
facilities of sterile injectables
in Vouvry, Switzerland.
Over 1 million pre-filled syringes
produced every year for intraarticular injections with Swiss
quality and unique know-how.
OSTENIL® pre-filled syringes contain
highly purified sodium hyaluronate
obtained by fermentation.
Restoring synovial balance in small joints
- HA obtained from bacterial fermentation
- HA 1% (10 mg/1 ml)
- Molecular weight:1-2 million Daltons
- 1 ml pre-filled syringe
- Terminal sterilisation for optimal safety:
the content and the outer surface of
the syringe are sterile.
Ostenil Mini
10 mg / 1 ml
• Cycle of 1-3 injections into small joints such
as those in the hand, foot, facet joints and the
temporomandibular joint.
• A single injection of OSTENIL® MINI
is as effective as an injection of steroid
in patients with rhizarthrosis.2
• OSTENIL® MINI improves joint mobility and
pain-free activity in the treatment of hallux
rigidus.1
• In temporomandibular joint disorders,
an injection of OSTENIL® MINI reduces
pain and improves joint function.3
1
2
3
Pons M et al. Foot Ankle Int 2007;28(1):38-42
Tourret LJ et al. Presented at the 10th World Congress on Osteoarthritis. December 8-11, 2005; poster P157.
Oliveras-Moreno JM et al. J Oral Maxillofac Surg 2008;66:2243-46
Designed for long-term relief in OA
- HA obtained from bacterial fermentation
- HA 1% (20 mg/2 ml)
- Molecular weight:1-2 million Daltons
- 2 ml pre-filled syringe
- Terminal sterilisation for optimal
safety: the content and the
outer surface of the syringe
are sterile.
• Treatment cycle of 3-5 weekly injections
into large joints.
• OSTENIL® provides long-lasting pain relief
and improves function in knee OA patients,
with excellent tolerability.4
Ostenil
20 mg / 2 ml
• OSTENIL® reduces pain and improves
function in patients with advanced OA
of the shoulder, who either refuse or are
considered medically unfit for shoulder
replacement surgery.6
• In patients suffering from hip OA, a
treatment cycle of 3 weekly injections of
OSTENIL® is effective in reducing pain over
12 months compared to lidocaine.5
4
5
6
Dreiser RL et al. Ann Rheum Dis 2012;71(Suppl3):584
Tsvetkova E et al. Ann Rheum Dis 2010;69(Suppl3):281
Funk L et al. Presented at the 9th World Conference of the Osteoarthritis Research Society International 2004; poster P338
®
Flexible treatment scheme with high dose HA 2%
- HA obtained from bacterial fermentation
- HA 2% (40 mg/2 ml)
- Molecular weight:1-2 million Daltons
- Mannitol 0.5% (10 mg/2 ml)
- 2 ml pre-filled syringe
- Terminal sterilisation for optimal
safety: the content and the outer
surface of the syringe are sterile.
• Mannitol-stabilised high dose HA 2%.
Mannitol acts as a free radical
scavenger which protects HA
from rapid depolymerisation.7
• The formulation offers the possibility of
increasing the intervals between injections.8
7
8
9
Mendoza G et al. Carbohydr Res 2007; 342: 96-102
Data on file
Borras-Verdera et al. Rev Esp Cir Ortop Traumatol 2012; 56(4): 274-80
Ostenil Plus
40 mg / 2 ml
• Sustained efficacy with reduced number of injections (1-3).8
• One injection of OSTENIL® PLUS reduces
pain and improves function in knee OA over
a period of at least 6 months.9
The healthy synovial
joint is in a state of
balance or homeostasis.
The hyaluronan in
the joint space is
continuously replaced,
but its concentration
and molecular weight
profile remain constant.
In osteoarthritis,
homeostasis is lost and
the hyaluronan in the
joint space becomes
depolymerised and
fragmented.10
The synovial fluid becomes less
viscous and its lubricating, shockabsorbing and filtering abilities
are reduced.11
The coating of hyaluronan over the
surface of the joint breaks down,
leaving the cartilage and synovium
exposed to mechanical and
inflammatory damage.12
Loss of homeostasis
in the osteoarthritic joint
The synovium becomes inflamed. As a result, it grows
more permeable to inflammatory molecules, which are
therefore able to enter the joint in increased numbers.12
Mensitieri M et al. J Mat Sci Mat Med 1995;6:130-7.
Balazs EA, Denlinger JL. J. Rheumatol 1993;20(Suppl 39):3-9.
12
Pelletier JP, Martel-Pelletier J. J Rheumatol 1993;20(Suppl 39):19-24.
13
Abatangelo G et al. Clin Orthop 1989;241:278-85.
14
Peyron JG. Osteoarthritis Cartilage, 1993;1:85-7.
15
Abatangelo G et al. Eur J Cell Biol 1998;49(Suppl 28):18.
16
Kvam BJ et al. Exp Cell Res 1995;218:79-86.
17
Presti D, Scott JE. Cell Biochem Funct 1994; 12:281-8.
18
Frizziero L et al. Clin Exp Rheumatol 1998;16:441-9.
19
Partsch G et al. Z Rheumatol 1989;48:123-8.
20
Karatay S et al. Ann Clin Lab Sci 2004;34:330-5.
21
Gotoh S et al. Ann Rheum Dis 1993;52:817-22.
22
Miyazaki K et al. Pharmacometrics 1984;28:1123-35.
23
Homandberg GA et al. Osteoarthritis Cartilage 1997;5:309-19.
24
Jubb RW et al. Ann Rheum Dis 2001; 60(Suppl 1):46.
25
Listrat V et al. Osteoarthritis Cartilage 1997;5:153-60.
26
Yasui T et al. Biomed Res 1992;13:343-8.
10
11
The articular cartilage is
gradually destroyed.13
Osteoarthritis is accompanied
by symptoms of pain,
inflammation and reduced mobility
The administration of exogenous hyaluronan increases
the viscosity of the synovial fluid, restoring its lubricating,
shock-absorbing and filtering properties.10,14
In addition, it re-establishes the protective coating
of hyaluronan over the inner surface of the joint and
increases the scavenging of free radicals.15,16,17
Exogenous hyaluronan
restores synovial balance
As a result of these changes, hyaluronan reduces
inflammation of the synovium.18-20
By masking the nociceptors, pain is also alleviated.11,21,22
Evidence exists suggesting that exogenous hyaluronan may slow the destruction of cartilage
®
23-26
GB
GB
Viscoelastic solution for injection into small joints
Instructions for Use
OSTENIL® mini
Sodium hyaluronate from fermentation 1.0 %. Viscoelastic solution for ­injection into small joints. Sterile by moist heat.
Composition:
1 ml isotonic solution contains 10.0 mg sodium hyaluro­nate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, water for i­njections.
Indications:
Pain and restricted mobility in degenerative and traumatic changes of small s­ ynovial joints, for example, the facet joints
of the lumbar spine, the saddle joint of the thumb, the interphalangeal joints of the fingers and toes, the p­ roximal joint
of the big toe and the temporomandibular joint. In the t­ reatment of larger joints, for example the knee, hip or shoulder,
OSTENIL® ­pre-filled syringes of 20 mg/2.0 ml should be used.
Contra-indications:
OSTENIL® mini should not be used in patients with ascertained h­ yper­sensitivity to any of its constituents.
Interactions:
No information on the incompatibility of OSTENIL® mini with other solutions for intraarticular use is available to date.
The concomitant use of an oral analgesic or anti-inflammatory drug during the first few days of treatment may be
helpful for the patient.
Undesirable effects:
Local secondary phenomena such as pain, feeling of heat, redness and s­ welling/joint effusion may occur in the joint
treated with OSTENIL® mini. Application of an ice pack onto the treated joint for five to ten minutes will reduce the
incidence of these events.
Dosage and administration:
Inject OSTENIL® mini into the affected joint once a week for a total of 1–3 injections. Several joints may be treated at
the same time. Depending on the severity of the joint disease the beneficial effects of a treatment cycle may last at
least six months. Repeat treatment cycles may be administered as required. In case of joint effusion it is advisable to
reduce the effusion by aspiration, rest, application of an ice pack and/or intraarticular cortico­steroid injection. Treatment
with OSTENIL® mini can be started two to three days later.
The contents and outer surface of the OSTENIL® mini pre-filled syringe are sterile as long as the sterile pack is intact.
Take the pre-filled s­ yringe out of the sterile pack, unscrew the Luer lock cap from the syringe, attach a s­ uitable ­needle
(for example 19 to 25 G) and secure it by turning slightly. Remove any air bubble, if present, before injection.
Precautions:
Caution should be exercised in patients with known hypersensitivity to drugs. The general precautions for intraarticular
injections should be observed, including measures to avoid joint infections. OSTENIL® mini should be ­injected accurately into the joint cavity, if necessary under imaging control. Avoid injec­tions into blood vessels or surrounding tissues!
As no ­clinical ­evidence is available on the use of hyaluronic acid in children, pregnant and lactating women or in inflammatory joint diseases such as rheumatoid arthritis or Bechterew disease, treatment with OSTENIL® mini is not
re­commended in these cases. Do not use if the pre-filled syringe or s­terile pack are damaged. Any solution not used
immediately after opening must be discarded. Otherwise the sterility is no longer guaranteed. Store between 2 °C and
25 °C! Do not use after the expiry date indicated on the box. Keep out of the reach of children.
Characteristics and mode of action:
Synovial fluid, which is viscoelastic due to the presence of hyaluronic acid, is found in all synovial joints where it ensures
normal, painless movement due to its lubricating and shock-absorbing properties. It is also responsible for the nutrition
of the cartilage. In degenerative joint disorders such as osteoarthritis, the viscoelasticity of the synovial fluid is markedly reduced thereby decreasing its lubricating and shock-absorbing functions. This increases mechanical ­loading of the
joint and cartilage destruction which ultimately results in pain and restricted mobility of the affected joint.
Supplementing this synovial fluid with intraarticular injections of highly purified hyaluronic acid can ameliorate the viscoelastic properties of synovial fluid. This improves its lubricating and shock-absorbing functions and reduces mechanical
­overload of the joint. As a rule this results in a decrease in pain and an improvement in joint mobility which may last for
several months after a t­reatment cycle.
Presentation:
One pre-filled syringe of 10 mg/1.0 ml OSTENIL® mini in a sterile pack.
OSTENIL® mini is a medical device. To be used by a physician only.
Last revision date: March 2011
Viscoelastic solution for injection into the joint cavity
Instructions for Use
OSTENIL®
Sodium hyaluronate from fermentation 1.0 %. Viscoelastic solution for injection into the joint cavity. Sterile by moist
heat.
Composition:
1 ml isotonic solution contains 10.0 mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, water for injections.
Indications:
Pain and restricted mobility in degenerative and traumatic changes of the knee joint and other synovial joints.
Contra-indications:
OSTENIL® should not be used in patients with ascertained hypersensitivity to any of its constituents.
Interactions:
No information on the incompatibility of OSTENIL® with other solutions for intra-articular use is available to date. The
concomitant use of an oral analgesic or anti-inflammatory drug during the first few days of treatment may be helpful for
the patient.
Undesirable effects:
Local secondary phenomena such as pain, feeling of heat, redness and swelling/joint effusion may occur in the joint
treated with OSTENIL®. Application of an ice pack onto the treated joint for five to ten minutes will reduce the incidence
of these events.
Dosage and administration:
Inject OSTENIL® into the affected joint once a week for a total of 3–5 injections. Several joints may be treated at
the same time. Depending on the severity of the joint disease the beneficial effects of a treatment cycle of five
intra-articular injections will last at least six months. Repeat treatment cycles may be administered as required.
In case of joint effusion it is advisable to reduce the effusion by aspiration, rest, application of an ice pack and/or
intra-articular corticosteroid injection. Treatment with OSTENIL® can be started two to three days later.
The content and the outer surface of the OSTENIL® pre-filled syringe are sterile as long as the sterile pack is intact. Take
the pre-filled syringe out of the sterile pack, unscrew the Luer lock cap from the syringe, attach a suitable needle
(for example 19 to 21 G) and secure it by turning slightly. Remove any air bubble, if present, before injection.
Precautions:
Caution should be exercised in patients with known hypersensitivity to drugs. The general precautions for intra-articular
injections should be observed, including measures to avoid joint infections. OSTENIL® should be injected accurately into
the joint cavity, if necessary under imaging control. Avoid injections into blood vessels or surrounding tissues! As no
clinical evidence is available on the use of hyaluronic acid in children, pregnant and lactating women or in inflammatory
joint diseases such as rheumatoid arthritis or Bechterew disease, treatment with OSTENIL® is not recommended in these
cases. Do not use if the pre-filled syringe or sterile pack are damaged. Any solution not used immediately after opening
must be discarded. Otherwise the sterility is no longer guaranteed. Store between 2 °C and 25 °C! Do not use after the
expiry date indicated on the box. Keep out of the reach of children.
Characteristics and mode of action:
Synovial fluid, which is viscoelastic due to the presence of hyaluronic acid, is found in all synovial joints, particularly the
large weight bearing joints, where it ensures normal, painless movement due to its lubricating and shock-absorbing
properties. It is also responsible for the nutrition of the cartilage. In degenerative joint disorders such as osteoarthritis,
the viscoelasticity of the synovial fluid is markedly reduced thereby decreasing its lubricating and shock-absorbing
functions. This increases mechanical loading of the joint and cartilage destruction which ultimately results in pain
and restricted mobility of the affected joint. Supplementing this synovial fluid with intra-articular injections of highly
purified hyaluronic acid can ameliorate the viscoelastic properties of synovial fluid. This improves its lubricating and
shock-absorbing functions and reduces mechanical overload of the joint. As a rule this results in a decrease in pain and
an improvement in joint mobility which may last for several months after a treatment cycle of five intra-articular
injections.
Presentation:
One pre-filled syringe of 20 mg/2.0 ml OSTENIL® in a sterile pack. Three pre-filled syringes of 20 mg/2.0 ml OSTENIL®
in sterile packs. Five pre-filled syringes of 20 mg/2.0 ml OSTENIL® in sterile packs.
OSTENIL® is a medical device. To be used by a physician only.
Last revision date: August 2011
®
%. Viskoelastische Lösung zur
hte Hitze.
Sodium hyaluronate from fermentation 1.0 %. Viscoelastic solution for
injection into the joint cavity. Sterile by moist heat.
Hyaluronate de sodium obtenu par fermentation 1,0 %. Solution viscoélastique
pour injection dans la cavité articulaire. Stérile par vapeur d’eau.
Hialuronato sódico obtenido por fermentación 1,0 %. Solución viscoelástica
para inyección en la cavidad articular. Estéril por calor húmedo.
Natriumhyaluronat sowie Naatriumdihydrogenphosphat und
Composition:
1 ml isotonic solution contains 10.0 mg sodium hyaluronate and sodium
chloride, disodium phosphate, sodium dihydrogen phosphate, water for
injections.
Composition :
1 ml de solution isotonique contient 10,0 mg de hyaluronate de sodium ainsi
que du chlorure de sodium, du phosphate disodique, du phosphate
monosodique et de l’eau pour préparation injectable.
Composición:
Cada ml de la solución isotónica contiene 10,0 mg de hialuronato sódico,
cloruro sódico, monohidrogenofosfato de sodio, dihidrogenofosfato de sodio
y agua para inyectables.
Indications:
Pain and restricted mobility in degenerative and traumatic changes of the
knee joint and other synovial joints.
Indications :
Douleur et diminution de la mobilité dans les altérations dégénératives et
traumatiques de l’articulation du genou et des autres articulations synoviales.
Indicaciones:
Dolor y limitación de la movilidad en cambios degenerativos y traumáticos de
la articulación de la rodilla y otras articulaciones sinoviales.
ähigkeit bei degenerativen und
s und anderer Synovialgelenke.
berempfindlichkeit gegen einen GB
:
®
OSTENIL
mit anderen
tic
solution
for intraintonicht
thebekannt
joint cavity
ng
geworden.
nehmenden schmerzstillenden
während der ersten Behandn.
Contra-indications:
OSTENIL® should not be used in patients with ascertained hypersensitivity to
GBone of the constituents.
Contre-indications :
OSTENIL® ne devrait pas être utilisé chez les patients avec des antécédents
Fd’hypersensibilité à l’un des constituants.
:
Viscoelastic solution for injection into AInteractions
the
joint
ce jour,
aucune cavity
donnée n’est Solución
disponible sur
l’incompatibilité para
d’OSTENIL
viscoelástica
Interactions:
®
No information on the incompatibility
of OSTENIL
with otherpour
solutions
Solution
viscoélastique
injection
dans
la cavité
for intra-articular use is available
to date. The
concomitant
use articulaire
of an oral
analgesic or anti-inflammatory drug during the first few days of treatment
may be helpful for the patient.
®
inyección
en la cavidad
articular
avec d’autres solutions à usage
intra-articulaire.
La prise simultanée
d’analgésiques ou d’une médication anti-inflammatoire par voie orale
pendant les premiers jours de traitement peut être utile au patient.
Contraindicaciones:
OSTENIL® no debe emplearse en pacientes con hipersensibilidad conocida
Ea alguno de sus componentes.
Interacciones:
Hasta la fecha no se dispone de ninguna información sobre la incompatibilidad de OSTENIL® con otras soluciones para uso intraarticular. El empleo
concomitante de un analgésico oral o una medicación antiinflamatoria durante los primeros días de tratamiento puede ser una ayuda para el paciente.
Instructions for Use
OSTENIL Plus
Sodium hyaluronate from fermentation 2.0 %. Viscoelastic solution for ­injection into the joint cavity. Sterile by moist
heat.
Composition:
1 ml isotonic solution (pH 7.3) contains 20.0 mg sodium hyaluronate from fermentation and sodium chloride, disodium
phosphate, sodium dihydrogenphosphate, mannitol and water for injections.
Indications:
Pain and restricted mobility in degenerative and traumatic changes of the knee joint and other synovial joints.
Contra-indications:
OSTENIL Plus should not be used in patients with ascertained hypersensitivity to one of the constituents.
Interactions:
No information on the incompatibility of OSTENIL Plus with other solutions for intra-articular use is available to date.
The concomitant use of an oral analgesic or anti-inflammatory drug during the first few days of treatment may be
helpful for the patient.
Side effects:
Local secondary phenomena such as pain, sensation of heat, redness and ­swelling may occur in the joint treated with
OSTENIL Plus. Application of an ice pack for five to ten minutes onto the treated joint will reduce the incidence of these
events.
Directions for use:
Inject OSTENIL Plus into the affected joint once a week for a total of 1–3 injections. Several joints may be treated at
the same time. Repeat treatment cycles may be administered as required. In case of joint effusion it is advisable to
reduce the effusion by aspiration, rest, application of an ice pack and/or intra-articular corticosteroid injection. Treatment
with OSTENIL Plus can be started two to three days later.
The content and the outer surface of the OSTENIL Plus pre-filled syringe are sterile as long as the sterile pack is intact.
Take the pre-filled syringe out of the sterile pack, unscrew the Luer lock cap from the syringe, attach a suitable needle
(for example 18 to 25 G) and secure it by turning slightly. Remove any air bubble, if present, before injection.
Precautions:
Caution should be exercised in patients with known hypersensitivity to drugs. The general precautions for intra-articular
injections should be observed, including measures to avoid joint infections. OSTENIL Plus should be injected accurately
into the joint cavity, if necessary under imaging control. Avoid ­injections into blood vessels or surrounding tissues! As no
clinical evidence is available on the use of hyaluronic acid in children, pregnant and lactating women or in inflammatory
joint diseases such as rheumatoid arthritis or Bechterew disease, treatment with OSTENIL Plus is not recommended in
these cases. Do not use if the pre-filled syringe or sterile pack are damaged. Any solution not used immediately after
opening must be discarded. Otherwise the sterility is no longer guaranteed. Store between 2 °C and 25 °C! Do not use
after the expiry date indicated on the box. Keep out of the reach of children!
Characteristics and mode of action:
Synovial fluid, which is viscoelastic due to the presence of hyaluronic acid, is found in all synovial joints, particularly the
large weight bearing joints, where it ensures normal, painless movement due to its lubricating and shock-absorbing
properties. It is also responsible for the nutrition of the cartilage. In degenerative joint disorders such as osteoarthritis,
the viscoelasticity of the synovial fluid is markedly reduced thereby decreasing its lubricating and shock-absorbing functions. This increases mechanical loading of the joint and cartilage destruction which ultimately results in pain and
restricted mobility of the affected joint. Supplementing this synovial fluid with intra-articular in­jections of highly purified
hyaluronic acid can ameliorate the viscoelastic properties of synovial fluid. This improves its lubricating and shockabsorbing functions and reduces mechanical overload of the joint. As a rule this results in a decrease in pain and an
improvement in joint mobility which may last for several months after a treatment cycle.
OSTENIL Plus is a transparent solution of natural and highly purified sodium hyaluronate obtained by fermentation and
is devoid of animal protein. OSTENIL Plus also contains mannitol, a free radical scavenger, which helps to stabilise the
chains of sodium hyaluronate. In biocompatibility studies, OSTENIL Plus was found to be particularly safe.
Presentation:
One pre-filled syringe of 40 mg / 2.0 ml OSTENIL Plus in a sterile pack.
OSTENIL Plus is a medical device. To be used by a physician only.
Last revision date:Présentation
December: 2010
Una jeringa prellenada de 20 mg/2,0 ml OSTENIL en un paquete estéril.
Side
Effets secondaires :
Efectos secundarios:
® effects:
Local secondary phenomena such as pain, feeling of heat, redness and
Des manifestations locales telles que douleur, chaleur, rougeur et gonflement
En la articulación tratada con OSTENIL®, pueden producirse fenómenos
USE
INSTRUCCIONES
PARA ELtraitée
USO par OSTENIL®.
swelling may MODE
occur in theD’EMPLOI
joint treated with OSTENIL®. Application of an ice
peuvent apparaître
au niveau de l’articulation
locales secundarios como dolor, sensación de calor, enrojecimiento e inflamaam
behandelten Gelenk lokale
Batch
number
®
®
ción. La aplicación de una bolsa de hielo
durante
cinco a diez minutos sobre
fühl, Rötungen und Schwellunpack for five to
ten minutes onto the treated joint will reduce the incidence of
L’application OSTENIL
d’une poche à glace pendant 5 à 10 minutes au niveau de la
OSTENIL
la articulación tratada reducirá la incidencia de estos síntomas.
auf das behandelte
Gelenk für solution these
zone traitée réduira
l’incidence
ces effets.
Hialuronato
sódicodeobtenido
por fermentación 1,0 %. Solución viscoelástica
mentation
1.0 %. Viscoelastic
for events. Hyaluronate de sodium obtenu par fermentation 1,0 %. Solution viscoélastique
solcher
Begleiterscheinungen.
para
inyección
en
la
cavidad
articular.
Estéril
por
calor
húmedo.
rile
by moist
heat.
pour
injection
dans
la
cavité
articulaire.
Stérile
par
vapeur
d’eau.
Directrices de uso:
Directions for use:
Dosage et administration :
®
®
Inyectar OSTENIL® en el interior de la articulación afectada una vez a la
ndung:
Inject OSTENIL
Injecter OSTENIL
into the affected
joint once a week for a total of 3–5
dans l’articulation atteinte une fois par semaine, pour un
Composición:
Composition
:
injections. Several
joints
may be
treated atcontient
the same
on the
total de 3 à 5Cada
injections.
peuvent 10,0
être traitées
semana con un total de 3–5 inyecciones. Pueden tratarse varias articulaciones
en
Abständen
in das
erkrankte and sodium
ml de Plusieurs
la soluciónarticulations
isotónica contiene
mg de simulhialuronato sódico,
10.0
mg sodium
hyaluronate
1 ml de
solution
isotonique
10,0time.
mg Depending
de hyaluronate
de sodium ainsi
jointdudisease
the beneficial
effects
a treatmentdisodique,
cycle of five
tanément. Encloruro
fonctionsódico,
du degré
de sévérité de l’affection
articulaire,
les effets de sodio
al mismo tiempo. Dependiendo de la gravedad de la patología articular, los
gleichzeitig
behandeltphosphate,
werden. water severity
monohidrogenofosfato
de sodio,
dihidrogenofosfato
sodium
dihydrogen
for of theque
chlorure
de sodium,
du ofphosphate
du phosphate
intra-articularmonosodique
injections willetlast
leastpour
six months.
Repeat
treatment cycles
bénéfiques d’un
cycle
traitement de 5 injections intra-articulaires se
efectos beneficiosos de un ciclo de tratamiento de cinco inyecciones intraann der Effekt einer Behandlung
y agua
paradeinyectables.
deatl’eau
préparation
injectable.
may be administered as required. In case of joint effusion it is advisable to
prolongeront au minimum 6 mois. Il est possible de répéter les cycles de
articulares durará como mínimo seis Expiry
meses.date
Pueden administrarse ciclos de
onate anhalten. Wiederholte
Indicaciones:
Indications :
reduce the effusion by aspiration, rest, application of an ice pack and /or
traitement si nécessaire. En cas d’épanchement articulaire, il est conseillé de
tratamiento repetidos según se precise. En caso de derrame articular, se
. Bei Vorliegen eines GelenkDolor y limitación de la movilidad en cambios degenerativos y traumáticos de
degenerative and traumatic changes of the
Douleur et diminution de la mobilité dans les ®altérations dégénératives et
intra-articular corticosteroid injection. Treatment with OSTENIL can be started
réduire l’épanchement par aspiration, repos, application d’une poche à glace
recomienda reducir el derrame mediante aspiración, reposo, aplicación de una
die Ruhigstellung des Gelenks
la articulación de la rodilla y otras articulaciones sinoviales.
nts.
traumatiques de l’articulation du genou et des autres articulations synoviales.
et/ou injection intra-articulaire d’un corticostéroïde. Le traitement avec
bolsa de hielo y/o inyección intraarticular de corticosteroides. El tratamiento
der die intra-artikuläre Verabtwo to three days later.
Contraindicaciones:
Contre-indications :
OSTENIL® pourra
con OSTENIL® puede iniciarse dos o tres días más tarde.
wei bis drei Tage danach wird
alors reprendre deux à trois jours après.
The content and the outer
surface of the OSTENIL® pre-filled syringe are sterile
OSTENIL® no debe emplearse en pacientes con hipersensibilidad conocida
OSTENIL® ne devrait pas être utilisé chez les patients avec des antécédents
patients with ascertained hypersensitivity to
Le contenu et la surface externe de la seringue pré-remplie d’OSTENIL®
El contenido y la superficie de la jeringa prellenada de OSTENIL® son estériles
as
®long as the sterile pack is intact. Take the pre-filled syringe out of the sterile
d’hypersensibilité à l’un des constituants.
a alguno de sus componentes.
pack, unscrew the Luer lock cap from the syringe, attach a suitable needle
ist, sind der Inhalt und die
demeurent stériles tant que l’emballage stérile reste intact. Sortir la seringue
siempre que el envoltorio estéril permanezca cerrado. Sacar la jeringa
: secure it by turning slightly. Remove any air
(for example Interactions
19 to 21 G) and
pré-remplie deInteracciones:
l’emballage stérile, dévisser la capsule de fermeture Luer de la
prellenada del envoltorio estéril y desenroscar
el tapón
Luer de la jeringa, unir
Die Fertigspritze wird aus der
For single
use only
®
®
atibility
of OSTENIL with
A ce before
jour, aucune
donnée n’est disponible sur l’incompatibilité d’OSTENIL
Hasta une
la fecha
no seappropriée
dispone de
información
other solutions
bubble, if present,
injection.
seringue, attacher
aiguille
(parninguna
exemple
19 à 21 sobre
G) etla incompati
una- aguja hipodérmica adecuada (por ejemplo de 19 a 21 G), asegurándola
m
Luer-Lock-Anschluss
abge®
bilidad
defixation
OSTENILen® con
to date.
The concomitant
use of an oral
avec d’autres solutions à usage intra-articulaire.
La prise simultanée
otras soluciones
paraAvant
uso intraarticular.
El empleo
s’assurer
de
sa
bonne
la
tournant
légèrement.
l’injection,
mediante un ligero giro. En caso de que haya alguna burbuja, elimínese antes
se 21
G) aufgesetzt
und diese
Precautions:
drug
during
the
first
few
days
of
treatment
d’analgésiques
ou
d’une
médication
anti-inflammatoire
par
voie
orale
concomitante
de
un
analgésico
oral
o
una
medicación
antiinflamatoria
duranveillez à retirer de la seringue toute bulle d’air éventuellement présente.
de la inyección.
r Injektion wird eine fallweise
Caution should be exercised in patients with known hypersensitivity to drugs.
pendant les premiers jours de traitement peut être utile au patient.
te los primeros días de tratamiento puede ser una ayuda para el paciente.
.
The general precautions for intra-articular injections should be observed,
Précautions :
Precauciones:
Effets to
secondaires
secundarios:
including measures
avoid joint: infections. OSTENIL® should be injected
Une attentionEfectos
particulière
doit être portée aux patients avec une hyperSe debe actuar con prudencia en pacientes con conocida hipersensibilidad a
®
uchbeiasPatienten
pain, feeling
of heat, redness and
Desthe
manifestations
telles que
chaleur,
rougeur
En la aux
articulación
tratadaLesconprécautions
OSTENIL ,générales
pueden producirse
sensibilité connue
médicaments.
liées aux fenómenos
los medicamentos. Guardar las precauciones habituales de las inyecciones
accurately into
joint cavity, locales
if necessary
underdouleur,
imaging
control.
Avoidet gonflement
mit bekannter
®
reatedVorsichtsmaßnahmen
with OSTENIL®. Application
apparaître
au niveau
de As
l’articulation
traitée par
localesculaires
secundarios
dolor, sensación
de mesures
calor, enrojecimiento
ice
.
Refer
to instruction
leaflet
injections
intra-arti
doiventcomo
être prises,
y compris les
destinées e inflamaintraarticulares, incluyendo las medidas
necesarias
para evitar
infecciones en
intopeuvent
blood vessels
or surrounding
tissues!
no clinical evidence
is OSTENIL
meine
für of aninjections
®
ción. La aplicación
bolsa de
hielo durante
cincoêtre
a diez
the treated
will reducezur
the incidenceavailable
of
d’une poche
pendant
5 à 10and
minutes
au niveau deà la
éviter une infection
articulaire. de
Lesuna
injections
d’OSTENIL
las articulaciones. OSTENIL® debe ser inyectado cuidadosamente en la
on L’appli
the usecation
of hyaluronic
acidàinglace
children,
pregnant
lactating
hließlich
derjoint
Maßnahmen
doivent
réali-minutos sobre
la articulación
la incidencia
de estos
traitée réduira
dence such
de cesaseffets.
women
or inzone
inflammatory
jointl’inci
diseases
rheumatoid arthritis or
sées spécifiquement
dans latratada
cavitéreducirá
articulaire,
si nécessaire
soussíntomas.
contrôle
cavidad articular, bajo control por imagen si es necesario. Evitar inyecciones
sollte korrekt in den Gelenk®
®
Bechterew diDosage
sease, treatment
with OSTENIL
scopique. Eviter
les injections
dans les vaisseaux sanguins et dans les tissus
en los vasos sanguíneos o los tejidos circundantes. No se disponen de datos
ldwandlerkontrolle. Injektionen
Directrices
de uso:
et administration
: is not recommended in these
®
!Inyectar
En l’absence
données
cliniques
l’emploi de
l’acideuna vez aclínicos
eiden!
keineaausreichenden
cases. Do notInjecter
use if the
pre-filled
syringe
or sterileatteinte
pack are
Any
OSTENILde® en
OSTENIL
ed jointDaonce
week for a total of 3–5
dans
l’articulation
unedamaged.
fois par semaine,
pourenvironnants
un
el interior
de lasur
articulación
afectada
la del uso del ácido hialurónico en niños, embarazadas y en mujeres
hyaluronique semana
chez l’enfant,
la femme
ou allaitante,
ou dans
lesarticulaciones
lactantes o en enfermedades inflamatorias de las articulaciones como la
säure bei
Kindern
sowieDepending
bei
not used
immediately
after opening
must
be discarded.
Otherwise
treated
at the
same time.
on solution
the
total de
3 à 5 injections.
Plusieurs
articulations
peuvent
être traitées simulcon un total
de 3–5enceinte
inyecciones.
Pueden tratarse
varias
affections inflamma
toires
articulaires
telles que
rhumatoïde
ou la articular,artritis
eibeneficial
Patienten
mit entzündlichen
no longer En
guaranteed.
between
2 °Cde
and
25 °C! Do
not les effets
effects
of a treatment cycle of the
five sterility istanément.
fonction duStore
degré
de sévérité
l’affection
articulaire,
al mismo
tiempo.
Dependiendo
de lal’arthrite
gravedad
de la patología
los reumatoide o la enfermedad de Bechterew. No se recomienda el
®
M.seBechterew,efectos
l’administration
d’OSTENIL
tratamiento con OSTENIL® en estosSterile
is und
vorliegen,
use after®thebénéfiques
expiry dated’un
indicated
box. Keep
of the reach
of
n’est
recommandée
chezinyecciones
ces
casos. by
Nomoist
utilizarheat
en caso de que la
at
leastM.sixBechterew,
months. Repeat
treatment cycles
cycle on
de the
traitement
de out
5 injections
intra-articulaires
beneficiosos
de un ciclo
depas
tratamiento
de cinco
intraNe pas
utiliser sidurará
la seringue
l’emballage
sont ciclosjeringa
nd.Fällen
empfohlen.
In casenicht
of joint
effusionNicht
it is advisablechildren.
to
prolongeront au minimum 6 mois. Il est possible de répéter les cyclespatients.
de
articulares
como pré-remplie
mínimo seisou
meses.
Puedenstérile
administrarse
de prellenada o la envoltura estéril estén deteriorados. Toda solución que
endommagés.
Toute
solution
non
utilisée
immédiatement
après
ouverture
no
erilverpackung
beschädigt
on,
rest, application
of ansind.
ice pack andCharacteristics
/or
traitement
si
nécessaire.
En
cas
d’épanchement
articulaire,
il
est
conseillé
de
tratamiento
repetidos
según
se
precise.
En
caso
de
derrame
articular,
sesea usada inmediatamente después de haber sido abierta deberá ser
and mode of action:
®
doit
être
jetée.
Sinon,
la
stérilité
n´est
plus
garantie.
Conserver
entre
2°C
et
desechada.
De
lo
contrario
no
se
garantizará
la
esterilidad
de la misma.
erwendet
wird,
muss
verworfen
tion. Treatment with OSTENIL can be started
par to
aspiration,
repos,ofapplication
recomienda reducir el derrame mediante aspiración, reposo, aplicación de una
Synovial fluid,réduire
which l’épanchement
is viscoelastic due
the presence
hyaluronic d’une
acid, ispoche à glace
25°C ! Ne pasbolsa
utiliser
d’expiration
mentionnée
sur la boîte. TenirEl tratamiento
Conservar entre 2 °C y 25 °C. No usar después de la fecha de caducidad
mehr gewährleistet.
et/ou injection
intra-articulaire
corticostéroïde.
traitement avec
deaprès
hielo lay/odate
inyección
intraarticular
de corticosteroides.
found in®all synovial
joints, particularly
the larged’un
weight
bearing joints,Lewhere
®
hors de portéecondesOSTENIL
enfants.® puede iniciarse dos o tres días más tarde.
indicada en la caja. Guardar fuera del alcance de los niños.
hten. Für Kinder® unzugänglich
OSTENIL
pourra
alors
reprendre
deux
à
trois
jours
après.
it
ensures
normal,
painless
movement
due
to
its
lubricating
and
shocke of the OSTENIL pre-filled syringe are sterile
®
®
absorbing properties.
It is also
for the de
nutrition
of the cartilage.
In d’OSTENIL
Caractéristiques
et mode
Características y modo de acción:
Le contenu
et laresponsible
surface externe
la seringue
pré-remplie
El contenido
y la d’action
superficie:de la jeringa prellenada de OSTENIL® son estériles
ct. Take the pre-filled syringe out of the sterile
degenerative demeurent
joint disorders
suchtant
as que
osteoarthritis,
viscoelasticity
of Sortir
the la seringue
Le liquide synovial,
liée àpermanezca
la présence cerrado.
d’acide hya
l- la jeringa
El líquido sinovial, que es viscoelástico debido a la presencia de ácido
p from the syringe, attach a suitable needle
stériles
l’emballagethestérile
reste intact.
siempredont
quela viscoélasticité
el envoltorio est
estéril
Sacar
Don‘t use if the sterile barrier is damaged
synovial
fluid
is
markedly
reduced
thereby
decreasing
lubricating
and Luer deuronique,
est prellenada
présent dans
les articulations
synoviales,
et particulièreanecure
Hyaluronsäure
viskoelastisch
hialurónico, se encuentra en todas las articulaciones sinoviales, particularmente
it by turning slightly. Remove any air
pré-remplie de l’emballage stérile, dévisser laitscapsule
de fermeture
la
del toutes
envoltorio
estéril y desenroscar
el tapón
Luer de la jeringa, unir
shock-absorbing
functions.
This increases
mechanical
loading
joint and
articulations
supportant
un poids(por
important,
desasegurándola
r,n.insbesondere in den großen
las articulaciones que soportan grandes pesos, donde asegura un movimiento
seringue,
attacher
une aiguille
appropriée
(parof the
exemple
19 à 21 G)ment
et dans lesuna
aguja hipodérmica
adecuada
ejemplooù
de il19permet
a 21 G),
cartilage destruction
resultsenin lapain
and restricted
mobility
mouvements mediante
normaux un
et sans
à ses
lubrifiantes
et
d ihrer schmierenden und stoßindoloro y normal debido a sus propiedades lubricantes y absorbentes de
s’assurerwhich
de saultimately
bonne fixation
tournant
légèrement.
Avant l’injection,
ligerodouleur
giro. Engrâce
caso de
quepropriétés
haya alguna
burbuja, elimínese
antes
of the affected
joint.
Supplementing
this toute
synovial
fluid
intra-articularprésente. d’absorption des
Il assure également l’apport nutritionnel du cartilage.
en, schmerzfreien Bewegungschoques. También es responsable de la nutrición del cartílago. En alteraciones
veillez
à retirer
de la seringue
bulle
d’airwith
éventuellement
de lachocs.
inyección.
atients with known hypersensitivity to drugs.
injections of highly purified hyaluronic acid can ameliorate the viscoelastic
Dans le cas d’affections dégénératives articulaires telles que l’ostéoarthrose,
gung des Gelenkknorpels mit
articulares degenerativas como osteoartritis, la viscoelasticidad del líquido
ra-articular injections should be observed,
Précautions :
Precauciones:
properties of synovial fluid. This improves its lubricating and shock-absorbing
la viscoélasticité du®liquide synovial est notablement diminuée, ce qui entraîne
Gelenkerkrankungen, wie
der
sinovial se reduce notablemente, disminuyendo sus funciones lubricantes y
®
nt infections. OSTENIL should be injected
Une attention particulière doit être portée aux patients avec une hyperSe debe actuar con prudencia en pacientes con conocida hipersensibilidad a
functions and reduces mechanical overload of the joint. As a rule this results
une réduction des fonctions lubrifiantes et d’absorption des chocs. Ceci
elenkschmiere erheblich beeinamortiguadoras de choques. Esto aumenta la carga mecánica de la articulasensibilité connue aux médicaments. Les précautions générales liées aux
los medicamentos. Guardar las precauciones habituales de las inyecciones
if necessary under imaging control. Avoid
in a decrease in pain and an improvement in joint mobility which may last for
augmente la charge mécanique de l’articulation et la destruction du cartilage.
dämpfende Wirkung mindert.
ción y la destrucción del cartílago que finalmente produce dolor y limitación
injections intra-articulaires doivent être prises, y compris les mesures destinées
intraarticulares, incluyendo las medidas necesarias para evitar infecciones en
urrounding tissues! As no clinical evidence is
several months after a treatment cycle of five intra-articular injections. ®
Ces phénomènes ont pour conséquences une
mobilité réduite de l’articulation
des Gelenks und der Abbau des
de la movilidad de la articulación afectada. La suplementación de este líquido
à éviter une infection articulaire. Les injections d’OSTENIL doivent être réalilas articulaciones. OSTENIL® debe ser inyectado cuidadosamente en la
nic acid in children, pregnant and lactating
atteinte et l’apparition de douleurs.
supplémentation du liquide synovial
enen Gelenk zu Schmerzen und
sinovial con inyecciones intraarticulares de ácido hialurónico altamente puri® bajo Une
t diseases such as rheumatoid arthritisPresentation:
or
sées spécifiquement dans la cavité articulaire, si nécessaire sous contrôle
cavidad articular,
control por imagen si es necesario. Evitar inyecciones
par
des
injections
intra-articulaires
d’acide
hyaluronique
hautement
purifié
qualitative ®Aufbesserung der
ficado puede mejorar las propiedades viscoelásticas del líquido sinovial. Esto
®
One pre-filledscopique.
syringe ofEviter
20 mg/2.0
ml OSTENIL
in vaisseaux
a sterile pack.
ith OSTENIL is not recommended in these
les injections
dans les
sanguins et dans les tissus
en los vasos sanguíneos o los tejidos circundantes. No se disponen de datos
permet d’améliorer les propriétés viscoélastiques du liquide synovial. On
Verabreichung von hochreiner
mejora sus funciones lubricantes y de absorción de choques y reduce
®
Three pre-filled
syringes of!20Enmg/2.0
ml OSTENIL
in sterile
packs.sur l’emploi de l’acide
environnants
l’absence
de données
cliniques
clínicos del uso del ácido hialurónico en niños, embarazadas y en mujeres
d syringe or sterile pack are damaged. Any
observe une amélioration des propriétés lubrifiantes et d’absorption des chocs
enschaften der Gelenkschmiere
la sobrecarga mecánica de la articulación. Como resultado se logra una
®
Five
pre-filled
syringes
of
20
mg/2.0
ml
OSTENIL
in
sterile
packs.
hyaluronique chez l’enfant, la femme enceinte ou allaitante, ou dans les
lactantes o en enfermedades inflamatorias de las articulaciones como la
after opening must be discarded. Otherwise
ainsi qu’une diminution de la surcharge mécanique de l’articulation. En règle
und stoßdämpfende Wirkung
disminución del dolor y una mejoría de la movilidad articular que puede durar
® affections inflammatoires articulaires telles que l’arthrite rhumatoïde ou la
artritis reumatoide o la enfermedad de Bechterew. No se recomienda el
eed. Store between 2 °C and 25 °C! Do OSTENIL
not
is
a
medical
device.
To
be
used
by
a
physician
only.
générale, le résultat se traduit par une
diminution de la douleur et une
ng des Gelenks verringert. Das
varios meses después de un ciclo de tratamiento de cinco inyecciones intraM. Bechterew, l’administration d’OSTENIL® n’est pas recommandée chez ces
tratamiento con OSTENIL® en estos casos. No utilizar en caso de que la
ated on the box. Keep out of the reach of
amélioration de la mobilité articulaire qui peut durer pendant plusieurs mois
hmerzen und eine Verbesserung
articulares.
Last revision date: October 2010
patients. Ne pas utiliser si la seringue pré-remplie ou l’emballage stérile sont
jeringa prellenada o la envoltura estéril estén deteriorados. Toda solución que
après un cycle de traitement de 5 injections intra-articulaires.
Behandlungszyklus von fünf
endommagés. Toute solution non utilisée immédiatement après ouverture
no sea usada inmediatamente después de haber sido abierta deberá Presentaciones:
ser
action:
anhalten können.
Présentation
:
Una jeringa prellenada de 20 mg/2,0 ml OSTENIL® en un paquete estéril.
doit
être
jetée.
Sinon,
la
stérilité
n´est
plus
garantie.
Conserver
entre
2°C
et
desechada.
De
lo
contrario
no
se
garantizará
la
esterilidad
de
la
misma.
tic due to the presence of hyaluronic acid, is
®
Une seringueConservar
pré-remplie
de 220°Cmg/2,0
ml No
OSTENIL
Tres jeringas prellenadas de 20 mg/2,0 ml OSTENIL® en paquetes estériles.
dans undeemballage
25°C ! Ne pas utiliser après la date d’expiration mentionnée sur la boîte. Tenir
entre
y 25 °C.
usar después
la fecha de caducidad
ularly the large weight bearing joints, where
stérile.
Cinco jeringas prellenadas de 20 mg/2,0 ml OSTENIL® en paquetes estériles.
in Sterilverpackung.
hors de portée des enfants.
indicada en la caja. Guardar fuera del alcance de los niños.
vement due to its lubricating and shockTrois seringues pré-remplies de 20 mg/2,0 ml OSTENIL®, individuellement
l in Sterilverpackung.
Para uso médico exclusivo.
sponsible for the nutrition of the cartilage. In
Caractéristiques et mode d’action :
Características y modo de acción:
emballées dans un emballage stérile.
ml in Sterilverpackung.
h as osteoarthritis, the viscoelasticity of the
Le liquide synovial, dont la viscoélasticité est liée à la présence d’acide hyalEl líquido sinovial, que es viscoelástico debido a la presencia de ácido
Última revisión: Octubre 2010
Cinq seringues pré-remplies de 20 mg/2,0 ml OSTENIL®, individuellement
ced thereby decreasing its lubricating and
uronique, est présent dans toutes les articulations synoviales, et particulièrehialurónico, se encuentra en todas las articulaciones sinoviales, particularmente
emballées dans un emballage stérile.
ncreases mechanical loading of the joint and
ment dans les articulations supportant un poids important, où il permet des
las articulaciones que soportan grandes pesos, donde asegura un movimiento
à un
usageymédical
exclusivement.
mately results in pain and restricted mobility
mouvements normaux et sans douleur grâce à ses propriétés lubrifiantesRéservé
et
indoloro
normal debido
a sus propiedades lubricantes y absorbentes de
nting this synovial fluid with intra-articular
d’absorption des chocs. Il assure également l’apport nutritionnel du cartilage.
choques.
También
Dernière révision
: Octobre
2010es responsable de la nutrición del cartílago. En alteraciones
luronic acid can ameliorate the viscoelastic
Dans le cas d’affections dégénératives articulaires telles que l’ostéoarthrose,
articulares degenerativas como osteoartritis, la viscoelasticidad del líquido
mproves its lubricating and shock-absorbing
la viscoélasticité du liquide synovial est notablement diminuée, ce qui entraîne
sinovial se reduce notablemente, disminuyendo sus funciones lubricantes y
al overload of the joint. As a rule this results
une réduction des fonctions lubrifiantes et d’absorption des chocs. Ceci
amortiguadoras de choques. Esto aumenta la carga mecánica de la articula®
rovement in joint mobility which may last for
augmente la charge mécanique de l’articulation et la destruction du cartilage.
ción y la destrucción del cartílago que finalmente produce dolor y limitación
®
cycle of five intra-articular injections.
Ces phénomènes ont pour conséquences une mobilité réduite de l’articulation
de la movilidad de la articulación afectada. La suplementación de este líquido
®
atteinte et l’apparition de douleurs. Une supplémentation du liquide synovial
sinovial con inyecciones intraarticulares de ácido hialurónico altamente puripar des injections intra-articulaires d’acide hyaluronique hautement purifié
ficado puede mejorar las propiedades viscoelásticas del líquido sinovial. Esto
2.0 ml OSTENIL® in a sterile pack.
permet
d’améliorer
les
propriétés
viscoélastiques
du
liquide
synovial.
On
mejora sus funciones lubricantes y de absorción de choques y reduce
g/2.0 ml OSTENIL® in sterile packs.
observe une amélioration des propriétés lubrifiantes et d’absorption des chocs
la sobrecarga mecánica de la articulación. Como resultado se logra una
/2.0 ml OSTENIL® in sterile packs.
®
ainsi qu’une diminution de la surcharge mécanique
de l’articulation. En règle
disminución del dolor y una mejoría de la movilidad articular que puede durar
e. To be used by a physician only.
générale, le résultat se traduit par une diminution de la douleur et une
varios meses después de un ciclo de tratamiento de cinco inyecciones intra®
amélioration de la mobilité articulaire qui peut durer pendant plusieurs mois
articulares.
après un cycle de traitement de 5 injections intra-articulaires.
Presentaciones:
0406105/7 0762H
Réservé à un usage médical exclusivement.
Dernière révision : Octobre 2010
For single use only
Refer to instruction leaflet
Sterile by moist heat
Don‘t use if the sterile barrier is damaged
TRB Chemedica AG
Richard-Reitzner-Allee 1
85540 Haar/München, Germany
®
Une seringue pré-remplie de 20 mg/2,0 ml OSTENIL® dans un emballage
stérile.
Trois seringues pré-remplies de 20 mg/2,0 ml OSTENIL®, individuellement
emballées dans un emballage stérile.
Cinq seringues pré-remplies de 20 mg/2,0 ml OSTENIL®, individuellement
emballées dans un emballage stérile.
Expiry date
Tres jeringas prellenadas de 20 mg/2,0 ml OSTENIL® en paquetes estériles.
Cinco jeringas prellenadas de 20 mg/2,0 ml OSTENIL® en paquetes estériles.
Para uso médico exclusivo.
Última revisión: Octubre 2010
TRB CHEMEDICA AG
Richard-Reitzner-Allee 1
85540 Haar/München, Germany
TRB CHEMEDICA AG
Richard-Reitzner-Allee 1
85540 Haar/München, Germany
Printed in 10/12
Ostenil line, Designed for
®
long-term relief in OA
TRB CHEMEDICA INTERNATIONAL SA - Rue Michel-Servet 12 - P.O. Box 352 - CH-1211 Geneva 12 - Switzerland
Tel. +41 22 703 49 00 - Fax +41 22 703 49 01 - e-mail: [email protected] - www.trbchemedica.com